Søiland Håvard, Skaland Ivar, Janssen Emiel A M, Gudlaugsson Einar, Körner Hartwig, Varhaug Jan Erik, Søreide Jon Arne, Baak Jan P A
Department of Surgery, Stavanger University Hospital, Stavanger, Norway.
Anticancer Res. 2008 Mar-Apr;28(2B):1151-60.
Apolipoprotein D (ApoD) is a promising prognostic and predictive factor in breast cancer, but the analysis methods and results vary.
Determination of ApoD content by immunoelectrophoresis in tumour cytosol (EPC), immunohistochemistry (IHC) in whole sections (WS) and tissue micro arrays (TMA) were compared in 283 breast carcinomas.
With EPC, 45% and with IHC, 71% of the tumours were ApoD-positive. Correlation between the degrees of ApoD positivity by ECP and IHC was poor (R2=0.04), caused by higher sensitivity of the IHC (resulting in many ECP negative carcinomas being IHC positive) and ApoD positivity of normal tissues and cysts (resulting in ApoD positivity by ECP in up to 33% of the IHC negative cases). Discrepancies between WS and TMA were considerable due to tumour heterogeneity.
In breast cancer, IHC ApoD determination is superior to EPC analysis, but intratumor heterogeneity must be carefully considered when using TMA technology.
载脂蛋白D（ApoD）是乳腺癌中一个很有前景的预后和预测因子，但分析方法和结果各不相同。
在283例乳腺癌中，比较了通过免疫电泳测定肿瘤细胞溶质（EPC）中的ApoD含量、在全切片（WS）和组织微阵列（TMA）中进行免疫组织化学（IHC）检测的情况。
采用EPC法，45%的肿瘤ApoD呈阳性；采用IHC法，71%的肿瘤ApoD呈阳性。EPC和IHC检测的ApoD阳性程度之间相关性较差（R2 = 0.04），这是由于IHC的敏感性较高（导致许多EPC阴性的癌组织IHC呈阳性）以及正常组织和囊肿的ApoD呈阳性（导致高达33%的IHC阴性病例EPC呈阳性）。由于肿瘤异质性，WS和TMA之间的差异相当大。
在乳腺癌中，IHC检测ApoD优于EPC分析，但使用TMA技术时必须仔细考虑肿瘤内异质性。
